Test Price
2,800 AED✅ Home Collection Available
KMT2A Gene (Wiedemann-Steiner Syndrome) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Corporate Oversight: Test supervised by Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA ID: 9294403). All procedures comply with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The KMT2A gene test employs Next-Generation Sequencing (NGS) to identify pathogenic variants causing Wiedemann-Steiner syndrome—a rare genetic disorder characterized by dysmorphic features, developmental delay, and increased cancer risk. This comprehensive assay is essential for paediatricians, clinical geneticists, and oncologists managing at-risk families in the UAE.
| Feature | Our Test (KMT2A NGS) | Closest Alternative |
|---|---|---|
| Methodology | Full gene NGS (coding + flanking intronic regions) | Sanger sequencing (limited to exons 2, 3, 4 only) |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks (fragmented analysis) |
| Diagnostic Yield | >99% sensitivity for point mutations and small indels | ~80% sensitivity, misses deep intronic variants |
Physician Insight & Safety Protocols
“The KMT2A gene is a critical regulator of chromatin remodelling; mutations here can present with a wide phenotypic spectrum. This NGS-based test offers the resolution needed for precise diagnosis, but results must always be interpreted within the full clinical context, including dysmorphology examination and family pedigree analysis.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Advisory Note
⚠️ Medical Guidance: Do not discontinue any prescribed medication or alter treatment based solely on genetic test results. Always consult your supervising physician.
Patient Safety & Exclusion Criteria
- Exclusion: Recent blood transfusion (less than 2 weeks) may interfere with DNA purity; reschedule collection.
- Exclusion: Inadequate clinical history or absence of a genetic counselling session (mandatory per UAE genetic testing laws).
- Red Flag: If patient exhibits acute leukaemic symptoms (unexplained bruising, fever, severe bone pain), immediate haematology/oncology referral is required—this test is not for acute diagnosis.
- Red Flag: For minors, consent must comply with Federal Decree-Law No. 4 of 2016 on Medical Liability; testing without parental/guardian consent is prohibited.
Patient FAQ & Clinical Guidance
1. What is the KMT2A gene test for?
Snippet: The KMT2A gene detects mutations causing Wiedemann-Steiner syndrome with 99.9% accuracy using Next-Generation Sequencing. It confirms clinical diagnosis, guides cancer surveillance, and helps family planning.
2. How is the sample collected and is home service available?
Snippet: A simple blood draw is collected at your home by our ISO-certified phlebotomy team using VIP Mobile Phlebotomy with temperature-controlled cold chain, available daily from 8 AM to 11 PM.
3. What are the clinical implications of a positive result?
Snippet: A positive KMT2A mutation confirms Wiedemann-Steiner syndrome, requiring specialist follow-up for development, congenital anomalies, and potential leukaemia screening protocols.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Compliance
This genetic test service fully complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All data is processed in ISO 27001-certified facilities. Patient consent is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. For minor patients, parental/guardian consent is mandatory. Genetic counselling is provided before and after testing, as required by UAE regulations.
Clinical & Logistical Metadata
| Test Name | KMT2A Gene (Wiedemann-Steiner Syndrome) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood (3-5 ml in EDTA tube) or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene coding and flanking intronic regions |
| ICD-10-CM Code | Q87.89, Z15.09, R62.50 |
| LOINC Code | 92915-6 |
| DHA Facility License & Address | Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians